董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christian Henry | 男 | Director | 58 | 33.19万美元 | 5.63 | 2026-06-11 |
| Jason Kelly | 男 | Chief Executive Officer and Director | 45 | 570.90万美元 | 235.79 | 2026-06-11 |
| Reshma Shetty | 女 | Director and President | 45 | 347.94万美元 | 487.23 | 2026-06-11 |
| Ross Fubini | 男 | Director | 50 | 31.74万美元 | 5.51 | 2026-06-11 |
| Sri Kosuri | 男 | Director | 46 | 30.71万美元 | 8.65 | 2026-06-11 |
| Harry E. Sloan | 男 | Director | 76 | 31.71万美元 | 30.34 | 2026-06-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jason Kelly | 男 | Chief Executive Officer and Director | 45 | 570.90万美元 | 235.79 | 2026-06-11 |
| Reshma Shetty | 女 | Director and President | 45 | 347.94万美元 | 487.23 | 2026-06-11 |
| Steven Coen | 男 | Chief Financial Officer | 60 | 133.23万美元 | 5.13 | 2026-06-11 |
董事简历
中英对照 | 中文 | 英文- Christian Henry
-
Christian Henry自2016年11月起担任董事，自2017年10月起担任Wave Life Sciences公司董事会主席。Henry先生目前担任生命科学上市公司太平洋生物科学的总裁兼首席执行官，他自2020年9月起担任该职位，并自2018年起在其董事会任职。Henry先生自2016年起在合成生物学上市公司Ginkgo Bioworks的董事会任职，此前曾于2021年4月至2021年12月在特殊目的收购上市公司CM Life Sciences III Inc.的董事会任职。Henry先生于2015年至2017年1月担任依诺米那，Inc.执行副总裁兼首席商务官，此前曾于2014年至2015年担任高级副总裁兼首席商务官，2012年至2014年担任高级副总裁兼Genomic Solutions总经理，2010年至2012年担任高级副总裁、首席财务官 & Life Sciences总经理，2009年至2010年担任企业发展高级副总裁兼首席财务官,2007年至2009年担任高级副总裁兼首席财务官,2005年至2006年担任副总裁兼首席财务官。在加入Illumina, Inc.之前，Henry先生于2003年至2005年担任Tickets.com，Inc.的首席财务官。从1999年到2003年，Henry先生担任Affymetrix, Inc.（于2016年被赛默飞世尔收购）的副总裁、财务兼公司控制人。1997年，Henry先生加入内克塔治疗（前身为Inhale Therapeutic Systems，Inc.），担任公司控制人，后于1997年至1999年担任首席会计官。1996年，Henry先生担任Sugen，Inc.的总会计经理。Henry先生于1992年在Ernst & Young LLP开始了他的职业生涯，他在该公司担任高级会计师直至1996年。Henry先生在加州大学圣地亚哥分校获得生物化学和细胞生物学学士学位，在加州大学欧文分校获得金融学硕士学位。
Christian Henry has served as a director since November 2016, and as Chair of Board since October 2017. Mr. Henry previously served as the President and Chief Executive Officer of Pacific Biosciences, a publicly traded life sciences company, from September 2020 to August 2026; Mr. Henry continues to serve on its board of directors, a position he has held since 2018. Mr. Henry has served on the board of directors of Ginkgo Bioworks, a publicly traded synthetic biology company, since 2016, and previously served on the board of directors of CM Life Sciences III Inc., a publicly traded special purpose acquisition company, from April 2021 through December 2021. Mr. Henry served as Executive Vice President & Chief Commercial Officer of Illumina, Inc. from 2015 through January 2017, and previously served as Senior Vice President & Chief Commercial Officer from 2014 to 2015, Senior Vice President & General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial Officer & General Manager Life Sciences from 2010 to 2012, Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010, Senior Vice President & Chief Financial Officer from 2007 to 2009, and Vice President & Chief Financial Officer from 2005 to 2006. Prior to joining Illumina, Inc., Mr. Henry served as the Chief Financial Officer of Tickets.com, Inc. from 2003 to 2005. From 1999 to 2003, Mr. Henry served as Vice President, Finance & Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr. Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later as its Chief Accounting Officer from 1997 to 1999. In 1996, Mr. Henry served as General Accounting Manager of Sugen, Inc. Mr. Henry began his career in 1992 at Ernst & Young LLP, where he was a Senior Accountant through 1996. Mr. Henry earned his B.A. in biochemistry and cell biology from the University of California, San Diego, and his M.B.A., with a concentration in finance, from the University of California, Irvine. - Christian Henry自2016年11月起担任董事，自2017年10月起担任Wave Life Sciences公司董事会主席。Henry先生目前担任生命科学上市公司太平洋生物科学的总裁兼首席执行官，他自2020年9月起担任该职位，并自2018年起在其董事会任职。Henry先生自2016年起在合成生物学上市公司Ginkgo Bioworks的董事会任职，此前曾于2021年4月至2021年12月在特殊目的收购上市公司CM Life Sciences III Inc.的董事会任职。Henry先生于2015年至2017年1月担任依诺米那，Inc.执行副总裁兼首席商务官，此前曾于2014年至2015年担任高级副总裁兼首席商务官，2012年至2014年担任高级副总裁兼Genomic Solutions总经理，2010年至2012年担任高级副总裁、首席财务官 & Life Sciences总经理，2009年至2010年担任企业发展高级副总裁兼首席财务官,2007年至2009年担任高级副总裁兼首席财务官,2005年至2006年担任副总裁兼首席财务官。在加入Illumina, Inc.之前，Henry先生于2003年至2005年担任Tickets.com，Inc.的首席财务官。从1999年到2003年，Henry先生担任Affymetrix, Inc.（于2016年被赛默飞世尔收购）的副总裁、财务兼公司控制人。1997年，Henry先生加入内克塔治疗（前身为Inhale Therapeutic Systems，Inc.），担任公司控制人，后于1997年至1999年担任首席会计官。1996年，Henry先生担任Sugen，Inc.的总会计经理。Henry先生于1992年在Ernst & Young LLP开始了他的职业生涯，他在该公司担任高级会计师直至1996年。Henry先生在加州大学圣地亚哥分校获得生物化学和细胞生物学学士学位，在加州大学欧文分校获得金融学硕士学位。
- Christian Henry has served as a director since November 2016, and as Chair of Board since October 2017. Mr. Henry previously served as the President and Chief Executive Officer of Pacific Biosciences, a publicly traded life sciences company, from September 2020 to August 2026; Mr. Henry continues to serve on its board of directors, a position he has held since 2018. Mr. Henry has served on the board of directors of Ginkgo Bioworks, a publicly traded synthetic biology company, since 2016, and previously served on the board of directors of CM Life Sciences III Inc., a publicly traded special purpose acquisition company, from April 2021 through December 2021. Mr. Henry served as Executive Vice President & Chief Commercial Officer of Illumina, Inc. from 2015 through January 2017, and previously served as Senior Vice President & Chief Commercial Officer from 2014 to 2015, Senior Vice President & General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial Officer & General Manager Life Sciences from 2010 to 2012, Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010, Senior Vice President & Chief Financial Officer from 2007 to 2009, and Vice President & Chief Financial Officer from 2005 to 2006. Prior to joining Illumina, Inc., Mr. Henry served as the Chief Financial Officer of Tickets.com, Inc. from 2003 to 2005. From 1999 to 2003, Mr. Henry served as Vice President, Finance & Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr. Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later as its Chief Accounting Officer from 1997 to 1999. In 1996, Mr. Henry served as General Accounting Manager of Sugen, Inc. Mr. Henry began his career in 1992 at Ernst & Young LLP, where he was a Senior Accountant through 1996. Mr. Henry earned his B.A. in biochemistry and cell biology from the University of California, San Diego, and his M.B.A., with a concentration in finance, from the University of California, Irvine.
- Jason Kelly
-
Jason Kelly，我们的创始人之一，自2008年成立以来担任我们的董事会成员和首席执行官。Kelly博士曾担任CM Life Sciences IIInc.董事纳斯达克:CMII，一家专注于生命科学领域的特殊目的收购公司，自2021年2月首次公开募股以来。Kelly博士拥有麻省理工学院生物工程博士学位和化学工程和生物学学士学位。
Jason Kelly one of Ginkgo Bioworks Holdings, Inc.'s Founders, is the Chief Executive Officer and a member of Ginkgo's Board. Dr. Kelly previously served as a director of CM Life Sciences II Inc. (Nasdaq: CMII), a special purpose acquisition company with a focus on the life sciences sector in 2021. Dr. Kelly has a Ph.D. in Biological Engineering and a B.S. in Chemical Engineering and Biology from the Massachusetts Institute of Technology. - Jason Kelly，我们的创始人之一，自2008年成立以来担任我们的董事会成员和首席执行官。Kelly博士曾担任CM Life Sciences IIInc.董事纳斯达克:CMII，一家专注于生命科学领域的特殊目的收购公司，自2021年2月首次公开募股以来。Kelly博士拥有麻省理工学院生物工程博士学位和化学工程和生物学学士学位。
- Jason Kelly one of Ginkgo Bioworks Holdings, Inc.'s Founders, is the Chief Executive Officer and a member of Ginkgo's Board. Dr. Kelly previously served as a director of CM Life Sciences II Inc. (Nasdaq: CMII), a special purpose acquisition company with a focus on the life sciences sector in 2021. Dr. Kelly has a Ph.D. in Biological Engineering and a B.S. in Chemical Engineering and Biology from the Massachusetts Institute of Technology.
- Reshma Shetty
-
Reshma Shetty，我们的创始人之一，自2008年成立以来担任我们的董事会成员，总裁兼首席运营官。谢蒂博士目前在非营利组织“核威胁倡议”的生物咨询小组任职。谢蒂博士拥有麻省理工学院生物工程博士学位和犹他大学计算机科学学士学位。
Reshma Shetty one of Ginkgo Bioworks Holdings, Inc.'s Founders, is the President and a member of Ginkgo's Board. Dr. Shetty has a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology and a B.S. in Computer Science from the University of Utah. - Reshma Shetty，我们的创始人之一，自2008年成立以来担任我们的董事会成员，总裁兼首席运营官。谢蒂博士目前在非营利组织“核威胁倡议”的生物咨询小组任职。谢蒂博士拥有麻省理工学院生物工程博士学位和犹他大学计算机科学学士学位。
- Reshma Shetty one of Ginkgo Bioworks Holdings, Inc.'s Founders, is the President and a member of Ginkgo's Board. Dr. Shetty has a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology and a B.S. in Computer Science from the University of Utah.
- Ross Fubini
-
Ross Fubini预计将在本次发行结束时担任董事。Ross Fubini是一位早期技术投资者。Fubini先生自2017年以来创立了风险投资公司XYZ Ventures，并一直担任其董事总经理。他还于2017年联合创立了全球投资公司Village Global。Fubini先生是BeyondHQ，Piazza Technologies，Legion，Beneficial State Bank，Liferaft Risk Technologies，Inc.，Saltbox，Inc.，Oro Labs，Inc.，Auxilius Inc.，Pebble Health Inc.，Bureau Inc.，Sardine，Inc.和Smash的董事会成员。富比尼的投资包括Lendup、Optimizely和Metromile NASDAQ:MILE。任职XYZ公司之前，他曾担任Canaan Partners公司的合伙人（从2012年到2015年）、Kapor Capital公司（从2011年到2012年），在那里他曾专注于企业应用程序、金融科技和医疗保健IT空间的可防御业务。Fubini先生共同创立并发展了Cubetree，这是一家高德纳有远见的企业社会协作公司。2010年Cubetree被SuccessFactors（原NYSE:SFSF，现为SAP公司）收购后，Fubini先生担任SuccessFactors的副总裁。Fubini先生还在赛门铁克（原纳斯达克代码:SYMC），BEA/Plumtree（原纳斯达克代码:PLUM），Tellme Networks和Netscape（原纳斯达克代码:NSCP）担任工程领导职务。他拥有卡内基梅隆大学的工程和艺术学士学位。
Ross Fubini founded XYZ Venture Capital, a venture capital investment firm focused on startups across various sectors, in 2017, and serves as Managing Director. Mr. Fubini was an early stage investor in defense tech leader Anduril, cloud based building security breakout Verkada, and modern insurance brokerage Newfront. Mr. Fubini also sits on multiple private company boards including Sardine and Legion Technologies. Mr. Fubini served as a director of Home Plate Acquisition Corp. from 2021 2023. Prior to XYZ, Mr. Fubini co founded Village Global and was an investor at both Canaan and Kapor Capital. He has held numerous operating roles, including CTO and co founder of CubeTree, which was sold to SuccessFactors in 2010, as well as led engineering divisions at Symantec and Plumtree Software.Mr. Fubini has advised and invested in over 200 companies across a range of stages and industries. Since 2010, Mr. Fubini has been involved with supporting executive teams to grow and scale revenue. - Ross Fubini预计将在本次发行结束时担任董事。Ross Fubini是一位早期技术投资者。Fubini先生自2017年以来创立了风险投资公司XYZ Ventures，并一直担任其董事总经理。他还于2017年联合创立了全球投资公司Village Global。Fubini先生是BeyondHQ，Piazza Technologies，Legion，Beneficial State Bank，Liferaft Risk Technologies，Inc.，Saltbox，Inc.，Oro Labs，Inc.，Auxilius Inc.，Pebble Health Inc.，Bureau Inc.，Sardine，Inc.和Smash的董事会成员。富比尼的投资包括Lendup、Optimizely和Metromile NASDAQ:MILE。任职XYZ公司之前，他曾担任Canaan Partners公司的合伙人（从2012年到2015年）、Kapor Capital公司（从2011年到2012年），在那里他曾专注于企业应用程序、金融科技和医疗保健IT空间的可防御业务。Fubini先生共同创立并发展了Cubetree，这是一家高德纳有远见的企业社会协作公司。2010年Cubetree被SuccessFactors（原NYSE:SFSF，现为SAP公司）收购后，Fubini先生担任SuccessFactors的副总裁。Fubini先生还在赛门铁克（原纳斯达克代码:SYMC），BEA/Plumtree（原纳斯达克代码:PLUM），Tellme Networks和Netscape（原纳斯达克代码:NSCP）担任工程领导职务。他拥有卡内基梅隆大学的工程和艺术学士学位。
- Ross Fubini founded XYZ Venture Capital, a venture capital investment firm focused on startups across various sectors, in 2017, and serves as Managing Director. Mr. Fubini was an early stage investor in defense tech leader Anduril, cloud based building security breakout Verkada, and modern insurance brokerage Newfront. Mr. Fubini also sits on multiple private company boards including Sardine and Legion Technologies. Mr. Fubini served as a director of Home Plate Acquisition Corp. from 2021 2023. Prior to XYZ, Mr. Fubini co founded Village Global and was an investor at both Canaan and Kapor Capital. He has held numerous operating roles, including CTO and co founder of CubeTree, which was sold to SuccessFactors in 2010, as well as led engineering divisions at Symantec and Plumtree Software.Mr. Fubini has advised and invested in over 200 companies across a range of stages and industries. Since 2010, Mr. Fubini has been involved with supporting executive teams to grow and scale revenue.
- Sri Kosuri
-
Sri Kosuri，自2019年以来一直担任Octant，Inc.（“Octant”）的首席执行官，该公司是一家位于加利福尼亚州埃默里维尔的私营药物发现公司。他之前是加州大学洛杉矶分校化学和生物化学系的副教授，他的实验室在那里开发了合成生物学、基因组学和生物化学方面的技术。Kosuri博士此前曾在哈佛大学WYSS研究所工作，在那里他构建了基因合成、DNA信息存储、基因编辑和大规模多重分析方面的众多技术。作为科学顾问委员会的成员，他帮助建立了Gen9，这是一家基因合成公司，后来于2017年被该公司收购，并帮助创办了Joule Unlimited，这是一家工程藻类转化为生物燃料的公司。他是Searle学者（2015年）、NIHNew Innovator（2014年），在麻省理工学院获得生物工程理学博士学位，在加州大学伯克利分校获得生物工程理学学士学位。
Sri Kosuri has been the chief executive officer of Octant, Inc. ("Octant"), a private, drug discovery company based in Emeryville, California since 2019. He was previously an associate professor at UCLA in the Chemistry and Biochemistry Department where his lab developed technologies in synthetic biology, genomics, and biochemistry. Dr. Kosuri previously worked at the Wyss Institute at Harvard University, where he built numerous technologies in gene synthesis, DNA information storage, gene editing, and large scale multiplexed assays. He helped build Gen9, a gene synthesis company later acquired by the Company in 2017, as a member of its scientific advisory board and helped start Joule Unlimited, an engineered algae to biofuel company. He is a Searle Scholar (2015), an NIH New Innovator (2014), and received his Doctor of Science in Biological Engineering at MIT and Bachelor of Science in Bioengineering at UC Berkeley. - Sri Kosuri，自2019年以来一直担任Octant，Inc.（“Octant”）的首席执行官，该公司是一家位于加利福尼亚州埃默里维尔的私营药物发现公司。他之前是加州大学洛杉矶分校化学和生物化学系的副教授，他的实验室在那里开发了合成生物学、基因组学和生物化学方面的技术。Kosuri博士此前曾在哈佛大学WYSS研究所工作，在那里他构建了基因合成、DNA信息存储、基因编辑和大规模多重分析方面的众多技术。作为科学顾问委员会的成员，他帮助建立了Gen9，这是一家基因合成公司，后来于2017年被该公司收购，并帮助创办了Joule Unlimited，这是一家工程藻类转化为生物燃料的公司。他是Searle学者（2015年）、NIHNew Innovator（2014年），在麻省理工学院获得生物工程理学博士学位，在加州大学伯克利分校获得生物工程理学学士学位。
- Sri Kosuri has been the chief executive officer of Octant, Inc. ("Octant"), a private, drug discovery company based in Emeryville, California since 2019. He was previously an associate professor at UCLA in the Chemistry and Biochemistry Department where his lab developed technologies in synthetic biology, genomics, and biochemistry. Dr. Kosuri previously worked at the Wyss Institute at Harvard University, where he built numerous technologies in gene synthesis, DNA information storage, gene editing, and large scale multiplexed assays. He helped build Gen9, a gene synthesis company later acquired by the Company in 2017, as a member of its scientific advisory board and helped start Joule Unlimited, an engineered algae to biofuel company. He is a Searle Scholar (2015), an NIH New Innovator (2014), and received his Doctor of Science in Biological Engineering at MIT and Bachelor of Science in Bioengineering at UC Berkeley.
- Harry E. Sloan
-
Harry E. Sloan自2025年8月起担任联合董事长。Sloan先生自2024年6月起担任Bold Eagle的联合董事长，并在2021年3月至2024年6月期间担任该公司的董事长兼首席执行官。Sloan先生于2021年11月至2024年5月期间担任Screaming Eagle的董事长，直至Screaming Eagle完成与Lionsgate Studios Corp.的BINCE组合，Sloan先生继续担任Lionsgate Studios Corp.的董事。从2021年12月至2025年5月期间，Sloan先生担任独立电影和电视制作公司Lions Gate Entertainment Corp.（纽约证券交易所代码：LGF.A，LGF.B）（“Lions Gate Parent”）的董事会成员。从2011年2月至2013年1月完成与BINCE的组合，并且他仍然是合并后公司的董事，自2005年10月至2009年8月，Sloan先生担任电影、电视、家庭娱乐以及戏剧制作和发行公司Metro Goldwyn Mayer，Inc.（“MGM”）的董事长兼首席执行官，此后继续担任非执行董事长至2010年12月。MGM于2010年申请破产保护。从1990年到2002年，Sloan先生担任欧洲广播集团SBS Broadcasting，S.A.（“SBS”）的董事长兼首席执行官，在船尾和中东欧经营商业电视、付费频道、广播电台和相关印刷厂，他于1990年创立了这家公司，并继续担任执行董事长至2005年。1999年，SBS成为Lions Gate Parent的最大股东。Sloan先生于2004年4月至2005年3月担任Lions Gate Parent董事会主席。从1983年到1989年，Sloan先生是新世界娱乐有限公司的联合主席，这是一家独立的电影和电视制作公司。
Harry E. Sloan is a founder, former public company CEO and a leading investor in the media, entertainment and technology industries. Mr. Sloan is the Chairman and CEO of Eagle Equity Partners II, LLC. Under Mr. Sloan's leadership, the company has acquired and taken public, through SPACs, several digital media companies including, during 2020, DraftKings and mobile gaming company Skillz. Mr. Sloan has been at the forefront and evolution of the video gaming industry as one of the founding investors and a Board Member of Zenimax/Bethesda Game Studios, the award winning studio acquired by Microsoft in March 2021. Mr. Sloan co founded Soaring Eagle Acquisition Corp. (Nasdaq: SRNGU), which raised $1.725 billion in its IPO in February 2021 and three months later announced its business combination with Boston based Ginkgo Bioworks, Inc. In January 2022, Mr. Sloan and his partners launched Screaming Eagle Acquisition Corp. With a closing of its initial public offering of 75,000,000 units, at a price of $10 per unit, Screaming Eagle is the largest IPO of a public acquisition vehicle since March 2021. Earlier in his career, Mr. Sloan was Chairman and CEO of MGM Studios and founded and led two public companies in the entertainment media arena, New World Entertainment and SBS broadcasting, S.A., one of Europe's largest broadcasters. Mr. Sloan is an Associate Professor at the University of California at Los Angeles's (UCLA) Anderson School of Management and serves on the UCLA Anderson School of Management Board of Visitors and the Executive Board of UCLA Theatre, Film and Television. Mr. Sloan has served as a director of Starz Entertainment Corp. (previously known as Lions Gate Entertainment Corporation) since December 2021 and DraftKings Inc. since April 2020. He was a director of Skillz, Inc. from December 2020 to August 2022, Soaring Eagle Acquisition Corp. from October 2020 until September 2021, Flying Eagle Acquisition Corp. from March 2020 until December 2020 and Diamond Eagle Acquisition Corp. from May 2019 until April 2020. Mr. Sloan is also a Trustee of The McCain Institute. Mr. Sloan received his B.A. degree from UCLA and J.D. degree from Loyola Law School. - Harry E. Sloan自2025年8月起担任联合董事长。Sloan先生自2024年6月起担任Bold Eagle的联合董事长，并在2021年3月至2024年6月期间担任该公司的董事长兼首席执行官。Sloan先生于2021年11月至2024年5月期间担任Screaming Eagle的董事长，直至Screaming Eagle完成与Lionsgate Studios Corp.的BINCE组合，Sloan先生继续担任Lionsgate Studios Corp.的董事。从2021年12月至2025年5月期间，Sloan先生担任独立电影和电视制作公司Lions Gate Entertainment Corp.（纽约证券交易所代码：LGF.A，LGF.B）（“Lions Gate Parent”）的董事会成员。从2011年2月至2013年1月完成与BINCE的组合，并且他仍然是合并后公司的董事，自2005年10月至2009年8月，Sloan先生担任电影、电视、家庭娱乐以及戏剧制作和发行公司Metro Goldwyn Mayer，Inc.（“MGM”）的董事长兼首席执行官，此后继续担任非执行董事长至2010年12月。MGM于2010年申请破产保护。从1990年到2002年，Sloan先生担任欧洲广播集团SBS Broadcasting，S.A.（“SBS”）的董事长兼首席执行官，在船尾和中东欧经营商业电视、付费频道、广播电台和相关印刷厂，他于1990年创立了这家公司，并继续担任执行董事长至2005年。1999年，SBS成为Lions Gate Parent的最大股东。Sloan先生于2004年4月至2005年3月担任Lions Gate Parent董事会主席。从1983年到1989年，Sloan先生是新世界娱乐有限公司的联合主席，这是一家独立的电影和电视制作公司。
- Harry E. Sloan is a founder, former public company CEO and a leading investor in the media, entertainment and technology industries. Mr. Sloan is the Chairman and CEO of Eagle Equity Partners II, LLC. Under Mr. Sloan's leadership, the company has acquired and taken public, through SPACs, several digital media companies including, during 2020, DraftKings and mobile gaming company Skillz. Mr. Sloan has been at the forefront and evolution of the video gaming industry as one of the founding investors and a Board Member of Zenimax/Bethesda Game Studios, the award winning studio acquired by Microsoft in March 2021. Mr. Sloan co founded Soaring Eagle Acquisition Corp. (Nasdaq: SRNGU), which raised $1.725 billion in its IPO in February 2021 and three months later announced its business combination with Boston based Ginkgo Bioworks, Inc. In January 2022, Mr. Sloan and his partners launched Screaming Eagle Acquisition Corp. With a closing of its initial public offering of 75,000,000 units, at a price of $10 per unit, Screaming Eagle is the largest IPO of a public acquisition vehicle since March 2021. Earlier in his career, Mr. Sloan was Chairman and CEO of MGM Studios and founded and led two public companies in the entertainment media arena, New World Entertainment and SBS broadcasting, S.A., one of Europe's largest broadcasters. Mr. Sloan is an Associate Professor at the University of California at Los Angeles's (UCLA) Anderson School of Management and serves on the UCLA Anderson School of Management Board of Visitors and the Executive Board of UCLA Theatre, Film and Television. Mr. Sloan has served as a director of Starz Entertainment Corp. (previously known as Lions Gate Entertainment Corporation) since December 2021 and DraftKings Inc. since April 2020. He was a director of Skillz, Inc. from December 2020 to August 2022, Soaring Eagle Acquisition Corp. from October 2020 until September 2021, Flying Eagle Acquisition Corp. from March 2020 until December 2020 and Diamond Eagle Acquisition Corp. from May 2019 until April 2020. Mr. Sloan is also a Trustee of The McCain Institute. Mr. Sloan received his B.A. degree from UCLA and J.D. degree from Loyola Law School.
高管简历
中英对照 | 中文 | 英文- Jason Kelly
Jason Kelly，我们的创始人之一，自2008年成立以来担任我们的董事会成员和首席执行官。Kelly博士曾担任CM Life Sciences IIInc.董事纳斯达克:CMII，一家专注于生命科学领域的特殊目的收购公司，自2021年2月首次公开募股以来。Kelly博士拥有麻省理工学院生物工程博士学位和化学工程和生物学学士学位。
Jason Kelly one of Ginkgo Bioworks Holdings, Inc.'s Founders, is the Chief Executive Officer and a member of Ginkgo's Board. Dr. Kelly previously served as a director of CM Life Sciences II Inc. (Nasdaq: CMII), a special purpose acquisition company with a focus on the life sciences sector in 2021. Dr. Kelly has a Ph.D. in Biological Engineering and a B.S. in Chemical Engineering and Biology from the Massachusetts Institute of Technology.- Jason Kelly，我们的创始人之一，自2008年成立以来担任我们的董事会成员和首席执行官。Kelly博士曾担任CM Life Sciences IIInc.董事纳斯达克:CMII，一家专注于生命科学领域的特殊目的收购公司，自2021年2月首次公开募股以来。Kelly博士拥有麻省理工学院生物工程博士学位和化学工程和生物学学士学位。
- Jason Kelly one of Ginkgo Bioworks Holdings, Inc.'s Founders, is the Chief Executive Officer and a member of Ginkgo's Board. Dr. Kelly previously served as a director of CM Life Sciences II Inc. (Nasdaq: CMII), a special purpose acquisition company with a focus on the life sciences sector in 2021. Dr. Kelly has a Ph.D. in Biological Engineering and a B.S. in Chemical Engineering and Biology from the Massachusetts Institute of Technology.
- Reshma Shetty
Reshma Shetty，我们的创始人之一，自2008年成立以来担任我们的董事会成员，总裁兼首席运营官。谢蒂博士目前在非营利组织“核威胁倡议”的生物咨询小组任职。谢蒂博士拥有麻省理工学院生物工程博士学位和犹他大学计算机科学学士学位。
Reshma Shetty one of Ginkgo Bioworks Holdings, Inc.'s Founders, is the President and a member of Ginkgo's Board. Dr. Shetty has a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology and a B.S. in Computer Science from the University of Utah.- Reshma Shetty，我们的创始人之一，自2008年成立以来担任我们的董事会成员，总裁兼首席运营官。谢蒂博士目前在非营利组织“核威胁倡议”的生物咨询小组任职。谢蒂博士拥有麻省理工学院生物工程博士学位和犹他大学计算机科学学士学位。
- Reshma Shetty one of Ginkgo Bioworks Holdings, Inc.'s Founders, is the President and a member of Ginkgo's Board. Dr. Shetty has a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology and a B.S. in Computer Science from the University of Utah.
- Steven Coen
Steven Coen于2023年5月1日加入公司，拥有超过30年的公共会计和公司财务领导经验，最近任职于Charles River Laboratories，这是一家面向制药和生物技术公司、政府机构和领先学术机构的全球合同研究组织，自2017年5月起担任公司副总裁兼公司财务总监。在加入Charles River之前，科恩在德勤会计师事务所（Deloitte & Touche LLP）从事审计业务超过17年后，曾在技术和医疗设备行业担任会计和财务领导职务。科恩先生在本特利大学获得会计学学士学位和管理学硕士学位，是马萨诸塞州的一名注册会计师。
Steven Coen has served as Ginkgo Bioworks Holdings, Inc.'s Chief Financial Officer since 2025 and previously served as Ginkgo Bioworks Holdings, Inc.'s Chief Accounting Officer from 2023 to 2025. Mr. Coen joined the Company with over 30 years of public accounting and corporate finance leadership experience, most recently with Charles River Laboratories, a global contract research organization for pharmaceutical and biotechnology companies, government agencies and leading academic institutions, where he served as the Corporate Vice President & Corporate Controller from 2017 to 2023. Prior to Charles River, Mr. Coen served in accounting and finance leadership roles in the technology and medical device industries after spending more than 17 years in the audit practice at Deloitte & Touche LLP. Mr. Coen earned a B.S. in Accounting and an A.S. in Management from Bentley University and is a Certified Public Accountant in Massachusetts.- Steven Coen于2023年5月1日加入公司，拥有超过30年的公共会计和公司财务领导经验，最近任职于Charles River Laboratories，这是一家面向制药和生物技术公司、政府机构和领先学术机构的全球合同研究组织，自2017年5月起担任公司副总裁兼公司财务总监。在加入Charles River之前，科恩在德勤会计师事务所（Deloitte & Touche LLP）从事审计业务超过17年后，曾在技术和医疗设备行业担任会计和财务领导职务。科恩先生在本特利大学获得会计学学士学位和管理学硕士学位，是马萨诸塞州的一名注册会计师。
- Steven Coen has served as Ginkgo Bioworks Holdings, Inc.'s Chief Financial Officer since 2025 and previously served as Ginkgo Bioworks Holdings, Inc.'s Chief Accounting Officer from 2023 to 2025. Mr. Coen joined the Company with over 30 years of public accounting and corporate finance leadership experience, most recently with Charles River Laboratories, a global contract research organization for pharmaceutical and biotechnology companies, government agencies and leading academic institutions, where he served as the Corporate Vice President & Corporate Controller from 2017 to 2023. Prior to Charles River, Mr. Coen served in accounting and finance leadership roles in the technology and medical device industries after spending more than 17 years in the audit practice at Deloitte & Touche LLP. Mr. Coen earned a B.S. in Accounting and an A.S. in Management from Bentley University and is a Certified Public Accountant in Massachusetts.